Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) has received an average rating of "Hold" from the fourteen brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and six have issued a buy recommendation on the company. The

Osaic Holdings Inc. grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 80.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 53,448 shares of the biopharmaceutical company's stock after acquiring an additional 23,910 shares during the period. Osaic

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Guru Stock PicksCI Select Canadian Equity Fund has made the following transactions:Reduce in TSX: ABX by 9.95%Sold out in TSX:DOLAdd in TSX: KEY by 27.62%New posi

RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) and represents the first and only subcutaneously (SC) administered targeted therapy for patients with EGFR+ mNSCLC. Compared to intravenous (IV) delivery, RYBREVANT FASPRO™ significantly reduced administration time from several hours to approximately five minutes and demonstrated an approximately fivefold reduction in administration-related reactions (ARRs) (13 percent in SC vs 66 percent in IV arm).

Halozyme is upgraded to a near-term Buy, driven by robust 2025–2028 royalty visibility and conservative valuation. HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering optionality but with uncertain long-term revenue durability. ENHANZE's U.S. patent expiry in 2027 raises post-2030 questions, but royalty streams and asset-light margins remain strong near-term.

Federated Hermes Inc. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 2.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 368,066 shares of the biopharmaceutical company's stock after purchasing an additional 8,529 shares during the period. Federated Hermes

Gabelli Funds LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 96.6% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 126,243 shares of the biopharmaceutical company's stock after selling 3,589,937 shares during the quarter. Gabelli Funds LLC owned

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:  HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics.